DR-5001
DR-ADV-301
Phase 3 mab completed
Quick answer
DR-5001 for Respiratory Tract Diseases is a Phase 3 program (mab) at TEVA PHARMACEUTICAL INDUSTRIES LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TEVA PHARMACEUTICAL INDUSTRIES LTD
- Indication
- Respiratory Tract Diseases
- Phase
- Phase 3
- Modality
- mab
- Status
- completed